For example, the use of siltuximab, an anti-IL-6 monoclonal antibody (99), could at least in theory result in favorable effects by lowering the pro-inflammatory and catabolic effects of elevated IL-6 levels on muscle, while at the same time also negatively influencing the ability of muscle and T cells to respond to exercise and influenza vaccination/infection, respectively. This evidence concerns the gene IL6 and influenza.